Reduced Intestinal Epithelial GPX4 Expression Predicts Postoperative Crohn’s Disease Recurrence and Offers a Novel Therapeutic Target
Posted inGastroenterology Internal Medicine news

Reduced Intestinal Epithelial GPX4 Expression Predicts Postoperative Crohn’s Disease Recurrence and Offers a Novel Therapeutic Target

A breakthrough study identifies epithelial Glutathione peroxidase 4 (GPX4) deficiency as a potent predictor of Crohn's disease recurrence after surgery. The research links this biomarker to endoplasmic reticulum stress and highlights selenium supplementation as a potential druggable strategy to improve patient outcomes.
Dietary Lipid Sequestration and Metabolic Rewiring in Colorectal Cancer: New Mechanistic Frontiers and Therapeutic Potential
Posted inClinical Updates Gastroenterology news Oncology

Dietary Lipid Sequestration and Metabolic Rewiring in Colorectal Cancer: New Mechanistic Frontiers and Therapeutic Potential

This review synthesizes recent evidence on how colorectal cancer tissues directly absorb extrinsic long-chain fatty acids from the intestinal lumen, particularly in right-sided tumors, and explores the critical interplay between lipid metabolism, the gut microbiome, and cancer cell proliferation.
Holding GLP-1/GIP Agonists Before Upper Endoscopy Reduces Residual Gastric Volume Risk: Insights from the OCULUS Randomized Trial
Posted inGastroenterology Internal Medicine news

Holding GLP-1/GIP Agonists Before Upper Endoscopy Reduces Residual Gastric Volume Risk: Insights from the OCULUS Randomized Trial

The OCULUS randomized trial demonstrates that continuing GLP-1/GIP agonists before upper endoscopy significantly increases the risk of clinically significant residual gastric volume compared to holding a single dose, providing crucial evidence for perioperative management guidelines.
Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma
Posted inGastroenterology news Oncology

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness and mitochondrial health, significantly enhancing the efficacy of immune checkpoint blockade.